Raising ambitions at Novo Nordisk an obvious move, says CEO

Novo Nordisk is growing fast, and its CEO is now directly indicating that new, more ambitious long-term goals will be implemented.

Photo: Valdemar Ren

Novo Nordisk's rapid growth has made company President and CEO Lars Fruergaard Jørgensen publically air thoughts of increasing the company's 2025 ambitions, which were set just 2 years ago.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs